Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Strengthens Evidence of Link Between Liver Cancer and Diabetes

March 2, 2005
By James L. Abbruzzese, MD, FACP
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International (ONI)is a compilation of selected news on important advances in the management ofgastrointestinal cancers over the past year, as reported in ONI. Guest Editor, Dr.James L. Abbruzzese, comments on the reports included herein and discussesdevelopments in the clinical management of GI cancers, with a look at the impactof targeted agents with cytotoxic chemotherapy, first-line and adjuvant therapies foradvanced disease, and the role of statins and COX-2 inhibitors in prevention.

SEATTLE-Diabetics may facethree times the risk of liver cancer,according to data from a new study. Anumber of epidemiological studieshave "suggested a relationship betweensome cancer types and diabetes, andthe most consistent results have beenfor cancers of the liver and the pancreas,"said Marie-Claude Rousseau, PhD,a postdoctoral fellow, in the Departmentof Social and Preventive Medicine,at the University of MontrealFaculty of Medicine."Some biological mechanisms havebeen proposed to suggest how diabetesaffects the risk of cancer, but to thisday, they remain only hypothetical. Soclearly, the question of whether cancerrisk is associated with diabetes isstill open," Dr. Rousseau said. Shepresented the findings at the AmericanAssociation for Cancer ResearchThird Annual International Conferenceon Frontiers in Cancer PreventionResearch (abstract 195).The investigators used data collectedfrom a study conducted in Montreal during the 1980s designed to addressworkplace factors and the risk ofcancer among men. The large population-based multisite case-controlstudy included information about priordiagnosis for diabetes, age at diagnosis,and medication use for diabetes.The study sample was comprisedof 3,288 male patients who had beenrecently diagnosed with cancer and509 healthy controls.Patients with diabetes also providedinformation about their usualheight and weight and lifestyle factors."These are important to consider whenstudying diabetes and cancer risk,"Dr. Rousseau said.The investigative team analyzed theassociation between diabetes and 12different types of cancer. "Out of the20 different cancer types that weredocumented in this study, our analysesfocused on 12 types for which thenumber of patients was large enoughto provide sufficient statistical powerfor the analyses," she explained.Study ResultsAfter adjusting for body mass indexand other covariates, the risk ofliver cancer was found to be elevatedamong men who reported a prior diagnosisof diabetes. The adjusted oddsratio (OR) was 3.1. The proportion ofdiabetics was 24% among liver cancerpatients, while only 8% of controlsreported having diabetes."These estimates were slightly higherwhen we used a more stringent definitionof diabetes," Dr. Rousseau said.This definition included only thosesubjects who were taking medication.The adjusted odds ratio for liver cancerfor this subgroup was 3.9.An association was observed withpancreatic cancer, mostly due to recentlydiagnosed diabetes. "This maysuggest that diabetes was a result of thepancreatic cancer rather than the opposite,"Dr. Rousseau said.The researchers did not observe anyassociation with other cancers studied,including melanoma, non-Hodgkin's lymphoma, and cancers ofthe esophagus, stomach, colon,rectum, lung, prostate, bladder, andkidney."While this was not the first studyto examine the link between cancerand diabetes, key features of our studieswere that we could assess the risk ofseveral different cancer types in thesame population and that the patientswere newly diagnosed," Dr. Rousseausaid. "Also, we had information thatallowed us to adjust for important factors,such as body mass index, smoking,and alcohol consumption. In conclusion,our study is strengthening theevidence of a link between diabetesand liver cancer."Dr. Rousseau's colleagues in thestudy were Jack Siemiatycki, PhD, Universityof Montreal, and Marie-EliseParent, PhD, INRS-Institut Armand-Frappier, Laval, Quebec.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy
Panitumumab, Anti-EGFR MoAb,Promising in Colon Cancer
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer
Study Strengthens Evidence of Link Between Liver Cancer and Diabetes
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Capecitabine Equal to Bolus 5-FU/LV in Adjuvant Therapy for Colon Cancer
Three Adjuvant 5-FU/RT Regimens Are Equally Effective
Single-Agent Cetuximab Active in Patients With Refractory Colon Cancer
XELIRI Shows Promise as First-Line Treatment for Advanced Colorectal Ca
UFT Provides ‘Equivalent’ Survival and Quality of Life to 5-FU in Stage II/III Colorectal Cancer
Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
2 KOLs are featured in this series.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
Advertisement

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The administration of proton beam therapy requires less specialized training but is also more expensive.

Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer

Ariana Pelosci
September 29th 2025
Article

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.


Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

Related Content
Advertisement

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.


Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.


The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The administration of proton beam therapy requires less specialized training but is also more expensive.

Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer

Ariana Pelosci
September 29th 2025
Article

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.


Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.